Stocktoria
Elicio Therapeutics, Inc. ELTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-02-05
Chart by TradingView
4/9
Piotroski F — financial health
-36.34
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | — | — | $2.3M | $27.5M |
| Operating income | -$37.7M | -$45.0M | -$35.7M | -$23.7M | -$39.3M |
| Net income | -$39.6M | -$51.9M | -$35.2M | -$28.2M | -$54.6M |
| Operating cash flow | -$37.0M | -$37.1M | -$32.7M | -$22.2M | -$52.6M |
| Free cash flow | -$37.0M | -$37.2M | -$32.8M | -$22.8M | -$53.0M |
| Total assets | $25.9M | $28.2M | $27.1M | $22.7M | $96.5M |
| Total liabilities | $24.2M | $39.5M | $15.8M | $13.7M | $15.0M |
| Shareholders' equity | $1.6M | -$11.3M | $11.4M | -$102.1M | -$74.5M |
| Ratios | |||||
| Operating margin | — | — | — | -1031.4% | -142.9% |
| Net margin | — | — | — | -1225.9% | -198.4% |
| FCF margin | — | — | — | -992.3% | -192.8% |
| Return on assets | -153.0% | -184.2% | -129.7% | -124.5% | -56.5% |
| Return on equity | -2418.8% | 458.8% | -309.5% | 27.6% | 73.2% |
| Debt / equity | 5.75× | -1.77× | — | — | -0.00× |
| Current ratio | 2.38 | 1.80 | 1.68 | 1.56 | 8.08 |
| Revenue growth | — | — | — | -91.6% | 855.1% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 121,631 | $1.3M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -36.34 (distress)
- Working capital / assets 0.433
- Retained earnings / assets -9.035
- EBIT / assets -1.458
- Equity / liabilities 0.068
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001601485 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.